Molecular identification and antifungal susceptibility profiles of Candida parapsilosis complex species isolated from culture collection of clinical samples.

INTRODUCTION Candida parapsilosis is a common yeast species found in cases of onychomycosis and candidemia associated with infected intravascular devices. In this study, we differentiated Candida parapsilosis sensu stricto, Candida orthopsilosis , and Candida metapsilosis from a culture collection containing blood and subungual scraping samples. Furthermore, we assessed the in vitro antifungal susceptibility of these species to fluconazole, itraconazole, voriconazole, posaconazole, amphotericin B, and caspofungin. METHODS Differentiation of C. parapsilosis complex species was performed by amplification of the secondary alcohol dehydrogenase (SADH) gene and digestion by the restriction enzyme Ban I. All isolates were evaluated for the determination of minimal inhibitory concentrations using Etest, a method for antifungal susceptibility testing. RESULTS Among the 87 isolates, 78 (89.7%) were identified as C. parapsilosis sensu stricto , five (5.7%) were identified as C. orthopsilosis , and four (4.6%) were identified as C. metapsilosis . Analysis of antifungal susceptibility showed that C. parapsilosis sensu strictoisolates were less susceptible to amphotericin B and itraconazole. One C. parapsilosis sensu stricto isolate was resistant to amphotericin B and itraconazole. Moreover, 10.2% of C. parapsilosis sensu stricto isolates were resistant to caspofungin. Two C. parapsilosis sensu strictoisolates and one C. metapsilosis isolate were susceptible to fluconazole in a dose-dependent manner. CONCLUSIONS We reported the first molecular identification of C. parapsilosiscomplex species in State of Goiás, Brazil. Additionally, we showed that although the three species exhibited differences in antifungal susceptibility profiles, the primary susceptibility of this species was to caspofungin.

[1]  K. Kamei,et al.  Isolation and Drug Susceptibility of Candida parapsilosis Sensu Lato and other Species of C. parapsilosis Complex from Patients with Blood Stream Infections and Proposal of a Novel LAMP Identification Method for the Species , 2015, Mycopathologia.

[2]  G. Criseo,et al.  Potential association of specific Candida parapsilosis genotypes, bloodstream infections and colonization of health workers' hands. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  S. Akçağlar,et al.  An investigation of Candida species isolated from blood cultures during 17 years in a university hospital , 2014, Mycoses.

[4]  R. Zancopé-Oliveira,et al.  Comparison of Commercial Methods and the CLSI Broth Microdilution to Determine the Antifungal Susceptibility of Candida parapsilosis Complex Bloodstream Isolates from Three Health Institutions in Rio de Janeiro, Brazil , 2014, Mycopathologia.

[5]  A. Amani,et al.  Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran. , 2014, Journal de mycologie medicale.

[6]  P. Escribano,et al.  Antifungal Resistance to Fluconazole and Echinocandins Is Not Emerging in Yeast Isolates Causing Fungemia in a Spanish Tertiary Care Center , 2014, Antimicrobial Agents and Chemotherapy.

[7]  K. Ferreira-Paim,et al.  Identification and antifungal susceptibility of fungi isolated from dermatomycoses , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  V. Leblond,et al.  Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy? , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[9]  M. Blanco-Blanco,et al.  Candida orthopsilosis fungemias in a Spanish tertiary care hospital: incidence, epidemiology and antifungal susceptibility. , 2014, Revista iberoamericana de micologia.

[10]  J. Meis,et al.  Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern , 2014, Infection.

[11]  J. Książyk,et al.  Candidaemia in a Polish tertiary paediatric hospital, 2000 to 2010 , 2014, Mycoses.

[12]  N. León-Sicairos,et al.  Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study. , 2013, The Journal of antimicrobial chemotherapy.

[13]  K. Makimura,et al.  Molecular identification and distribution profile of Candida species isolated from Iranian patients. , 2013, Medical mycology.

[14]  G. Bayramoğlu,et al.  Distribution, virulence attributes and antifungal susceptibility patterns of Candida parapsilosis complex strains isolated from clinical samples. , 2013, Medical mycology.

[15]  J. L. Fuentes-Allen,et al.  Prevalence and etiology of onychomycosis in the HIV-infected Mexican population. , 2013, European journal of dermatology : EJD.

[16]  G. González,et al.  Aspartyl proteinase, phospholipase, esterase and hemolysin activities of clinical isolates of the Candida parapsilosis species complex. , 2013, Medical mycology.

[17]  J. Echevarria,et al.  Epidemiology of Candidemia in Latin America: A Laboratory-Based Survey , 2013, PloS one.

[18]  M. Montagna,et al.  Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project) , 2013, Infection.

[19]  L. Hensgens,et al.  Comparison of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis adhesive properties and pathogenicity. , 2013, International journal of medical microbiology : IJMM.

[20]  E. G. Silva,et al.  Candidemia by Species of the Candida parapsilosis Complex in Children’s Hospital: Prevalence, Biofilm Production and Antifungal Susceptibility , 2013, Mycopathologia.

[21]  J. Pemán,et al.  Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital. , 2012, The Journal of antimicrobial chemotherapy.

[22]  E. Garza-González,et al.  Molecular characterization and antifungal susceptibility of the Candida parapsilosis species complex of clinical isolates from Monterrey, Mexico. , 2012, Medical mycology.

[23]  K. Garey,et al.  Echinocandin Resistance in Candida Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches , 2012, The Annals of pharmacotherapy.

[24]  M. Melhem,et al.  Prevalence, distribution and antifungal susceptibility profiles of Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis bloodstream isolates. , 2012, Journal of medical microbiology.

[25]  B. Juhász,et al.  Comparison of In Vitro and Vivo Efficacy of Caspofungin Against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans , 2012, Mycopathologia.

[26]  J. Gaudart,et al.  Interlaboratory Reproducibility of Etest Amphotericin B and Caspofungin Yeast Susceptibility Testing and Comparison with the CLSI Method , 2012, Journal of Clinical Microbiology.

[27]  G. Criseo,et al.  Molecular characterization of Italian Candida parapsilosis isolates reveals the cryptic presence of the newly described species Candida orthopsilosis in blood cultures from newborns. , 2012, Diagnostic microbiology and infectious disease.

[28]  B. Lebeau,et al.  Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. , 2011, The Journal of antimicrobial chemotherapy.

[29]  Maria R R Silva,et al.  Antifungal susceptibility patterns of yeasts and filamentous fungi isolated from nail infection , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[30]  G. Quindós,et al.  Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital. , 2011, The Journal of antimicrobial chemotherapy.

[31]  G. Bayramoğlu,et al.  [Genotypic identification and distribution patterns of Candida parapsilosis complex species (C.parapsilosis sensu stricto, C.metapsilosis and C.orthopsilosis) isolated from clinical samples]. , 2011, Mikrobiyoloji bulteni.

[32]  J. Pemán,et al.  Prospective Multicenter Study of the Epidemiology, Molecular Identification, and Antifungal Susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Isolated from Patients with Candidemia , 2011, Antimicrobial Agents and Chemotherapy.

[33]  H. Ibrahim,et al.  In vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia. , 2011, Journal of medical microbiology.

[34]  Yong-nian Shen,et al.  In Vitro Evaluation of Phospholipase, Proteinase, and Esterase Activities of Candida parapsilosis and Candida metapsilosis , 2011, Mycopathologia.

[35]  M. Arendrup,et al.  Echinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden , 2011, Journal of Clinical Microbiology.

[36]  C. Orsi,et al.  Candida metapsilosis as the least virulent member of the 'C. parapsilosis' complex. , 2010, Medical mycology.

[37]  Yu-Hsin Lin,et al.  Molecular epidemiology and antifungal susceptibility of Candida parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis in Taiwan. , 2010, Diagnostic microbiology and infectious disease.

[38]  M. Castanheira,et al.  Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species , 2010, Journal of Clinical Microbiology.

[39]  Burçe Yalçin,et al.  High incidence of Candida parapsilosis candidaemia in non-neutropenic critically ill patients: Epidemiology and antifungal susceptibility , 2010, Scandinavian journal of infectious diseases.

[40]  D. Stevens,et al.  Significant differences in drug susceptibility among species in the Candida parapsilosis group. , 2008, Diagnostic microbiology and infectious disease.

[41]  S. Lockhart,et al.  Geographic Distribution and Antifungal Susceptibility of the Newly Described Species Candida orthopsilosis and Candida metapsilosis in Comparison to the Closely Related Species Candida parapsilosis , 2008, Journal of Clinical Microbiology.

[42]  M. Cuenca‐Estrella,et al.  Prevalence and Susceptibility Profile of Candida metapsilosis and Candida orthopsilosis: Results from Population-Based Surveillance of Candidemia in Spain , 2008, Antimicrobial Agents and Chemotherapy.

[43]  X. S. Passos,et al.  Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital , 2007, Mycopathologia.

[44]  M. Maiden,et al.  Candida orthopsilosis and Candida metapsilosis spp. nov. To Replace Candida parapsilosis Groups II and III , 2005, Journal of Clinical Microbiology.

[45]  D. Snydman,et al.  Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. , 1998, The Journal of infectious diseases.

[46]  F. Fich,et al.  Candida Parapsilosis and Candida Guillermondii: Emerging Pathogens in Nail Candidiasis , 2014, Indian journal of dermatology.

[47]  A. Fusco-Almeida,et al.  Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. , 2013, Journal of medical microbiology.

[48]  M. Hallek,et al.  Comparison of killing activity of caspofungin against Candida parapsilosis , Candida orthopsilosis and Candida metapsilosis , 2008 .